Aurum Biosciences: Funding, Investors & Team (Sep 2026)
AURUM Biosciences Ltd develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.
Aurum Biosciences has raised $930k across 1 funding round on record, the most recent an undisclosed round of $930k announced in Jan 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aurum Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Aurum Biosciences Funding Rounds
Aurum Biosciences Founders and Leadership Team
Contact details for the Aurum Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →Aurum Biosciences Funding Compared to Other Biotechnology Startups
Aurum Biosciences' latest round of $930k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aurum Biosciences in Biotechnology and Glasgow
Companies Similar to Aurum Biosciences
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Aurum Biosciences Funding FAQs
What does Aurum Biosciences do?
AURUM Biosciences Ltd develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.
How much funding has Aurum Biosciences raised?
Aurum Biosciences has raised $930k across 1 round on record. The most recent is an undisclosed round of $930k announced in Jan 2024.
When did Aurum Biosciences last raise funding?
Aurum Biosciences' most recent funding round on record is an undisclosed round of $930k, announced in Jan 2024.
Who founded Aurum Biosciences?
FundedIQ lists Graeme Deuchar (Founder) at Aurum Biosciences.
Where is Aurum Biosciences headquartered?
Aurum Biosciences is based in Glasgow, United Kingdom.
How many employees does Aurum Biosciences have?
Aurum Biosciences is in the 1-10 employee band.
How does Aurum Biosciences' funding compare to other Biotechnology startups?
Aurum Biosciences' latest round of $930k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aurum Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aurum Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.